サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1547928

DNA修復薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global DNA Repair Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
DNA修復薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

DNA修復薬市場の世界需要は、2023年の70億2,000万米ドルから2032年には247億9,000万米ドル近くの市場規模に達すると推定され、調査期間2024～2032年のCAGRは15.05%です。

DNA損傷は遺伝物質の構造変化を引き起こします。DNA損傷はDNA構造に欠損や異常を生じさせ、DNAの突然変異を引き起こします。突然変異は必須タンパク質や酵素をコードする遺伝子で起こる。このように、DNA損傷はDNAの適切な機能と性能を妨げ、その結果、遺伝的障害を発症させるのです。しかし、人体には損傷を受けたDNA配列を修復する能力があります。DNA修復は、突然変異が起こった細胞を特定し、ゲノムをコードするDNA分子を修正することを含む、様々なプロセスの組み合わせです。ポリADPリボースポリメラーゼ（PARP）阻害剤などの特定の薬剤は、体内のDNA修復メカニズムを強化するために使用されます。DNA修復薬は、DNA損傷や遺伝子異常に関連する治療をサポートします。

市場力学

がんの有病率は世界中で急速に上昇しています。遺伝子の突然変異は、がんにつながる制御不能な細胞増殖を引き起こします。がんは、世界中で多数の死者を出している主要疾患のひとつです。がんの有病率の増加は、世界のDNA修復薬市場を推進しています。さらに、がんやその他の遺伝性疾患を治療するための先進的な次世代技術の採用が増加していることも需要を促進しています。主要メーカーは、DNA修復メカニズムをサポートする効果的な薬剤ソリューションを見つけるために、大規模な研究開発に投資しています。主要市場参入企業が獲得した戦略が世界市場を推進しています。COVID-19のパンデミックは、世界のDNA修復薬市場を強化する可能性が高い薬剤開発のR＆Dを支援しています。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールはDNA修復薬の世界市場における各セグメントを包括的に評価することもできます。DNA修復剤産業の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

DNA修復剤市場レポートのこのセクションでは、国別と地域別のセグメントに関する詳細なデータを提供し、それによって戦略担当者がそれぞれの製品またはサービスの対象層を特定する上で、今後のビジネス機会を支援します。

地域別分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおけるDNA修復薬市場の現在と将来の需要を明らかにする地域展望を取り上げます。さらに、著名な全地域における各用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 DNA修復薬-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカー一覧
    • 主要原材料の価格動向
  • 潜在的バイヤー一覧
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 DNA修復薬の世界市場分析：薬剤タイプ別

  • 薬剤タイプ別概要
  • 実績データと予測データ
  • 薬剤タイプ別分析
  • タラゾパリブ
  • オラパリブ
  • ニラパリブ
  • ルカパリブ
  • その他の薬剤タイプ

第6章 DNA修復薬の世界市場分析：用途別

  • 用途別概要
  • 実績データと予測データ
  • 用途別分析
  • 乳がん
  • 卵巣がん
  • 腹膜がん
  • 卵管がん
  • その他

第7章 DNA修復薬の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • その他

第8章 DNA修復薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 DNA修復薬企業の競合情勢

  • DNA修復薬の市場競合
  • 提携・協力・契約
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • AstraZeneca Plc
  • Onxeo
  • Johnson & Johnson
  • FoRx Therapeutics
  • AbbVie
  • Artios Pharma Limited
  • Pfizer Inc.
  • Breakpoint Therapeutics
  • Luciole Pharmaceuticals
  • Merck KGaA
  • ClovisOncology Inc.
  • GlaxoSmithKline Plc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Type (USD MN)
  • Talazoparib Market Sales By Geography (USD MN)
  • Olaparib Market Sales By Geography (USD MN)
  • Niraparib Market Sales By Geography (USD MN)
  • Rucaparib Market Sales By Geography (USD MN)
  • Other Drug Types Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Peritoneal Cancer Market Sales By Geography (USD MN)
  • Fallopian Tube Cancer Market Sales By Geography (USD MN)
  • Other Applications Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Other Distribution Channels Market Sales By Geography (USD MN)
  • Global DNA Repair Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of DNA Repair Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global DNA Repair Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Type
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Type (USD MN)
  • Talazoparib Market Sales By Geography (USD MN)
  • Olaparib Market Sales By Geography (USD MN)
  • Niraparib Market Sales By Geography (USD MN)
  • Rucaparib Market Sales By Geography (USD MN)
  • Other Drug Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Peritoneal Cancer Market Sales By Geography (USD MN)
  • Fallopian Tube Cancer Market Sales By Geography (USD MN)
  • Other Applications Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Other Distribution Channels Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11212424

The global demand for DNA Repair Drugs Market is presumed to reach the market size of nearly USD 24.79 Billion by 2032 from USD 7.02 Billion in 2023 with a CAGR of 15.05% under the study period 2024-2032.

DNA damage causes alteration of structure in genetic material. It causes the inclusion of deficiencies and abnormalities in the DNA structure, which leads to mutations in the DNA. The mutations take place in the genes coding for essential proteins or enzymes. Thus DNA damage hampers the proper functioning and performance of the DNA resulting in the development of genetic disorders. However, the human body is capable of repairing damaged DNA sequences. DNA repairing is a combination of processes altogether that includes identification of cells where the mutation has occurred and the correction of DNA molecules that are involved in the encoding genome. Certain drugs such as poly ADP ribose polymerase (PARP) inhibitors are used to enhance the body's DNA repairing mechanism. DNA repair drugs support the treatments related to DNA damage and genetic abnormalities.

MARKET DYNAMICS

The prevalence of cancer is rising rapidly across the globe. Mutations in the genes cause uncontrolled cell growth leading to cancer. Cancer is one of the major diseases responsible for a large number of deaths across the globe. The increasing prevalence of cancer is propelling the global DNA repair drugs market. Furthermore, the growing adoption of advanced next-generation technologies to treat cancer and other genetic diseases is fueling demand. The key manufacturers are investing in R & D on a large scale to find effective drug solutions to support the DNA repair mechanism. The strategies acquired by key market players are propelling the global market. COVID-19 pandemic is supporting the R & D in drug development that is likely to enhance the global DNA repair drugs market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of DNA Repair Drugs. The growth and trends of DNA Repair Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the DNA Repair Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

  • Talazoparib
  • Olaparib
  • Niraparib
  • Rucaparib
  • Other Drug Types

By Application

  • Breast Cancer
  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer
  • Other Applications

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the DNA Repair Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the DNA Repair Drugs market include AstraZeneca Plc, Onxeo, Johnson & Johnson, FoRx Therapeutics, AbbVie, Artios Pharma Limited, Pfizer Inc., Breakpoint Therapeutics, Luciole Pharmaceuticals, Merck KGaA, ClovisOncology Inc., GlaxoSmithKline Plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. DNA REPAIR DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DRUG TYPE

  • 5.1. Overview By Drug Type
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Type
  • 5.4. Talazoparib Historic and Forecast Sales By Regions
  • 5.5. Olaparib Historic and Forecast Sales By Regions
  • 5.6. Niraparib Historic and Forecast Sales By Regions
  • 5.7. Rucaparib Historic and Forecast Sales By Regions
  • 5.8. Other Drug Types Historic and Forecast Sales By Regions

6. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY APPLICATION

  • 6.1. Overview By Application
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Application
  • 6.4. Breast Cancer Historic and Forecast Sales By Regions
  • 6.5. Ovarian Cancer Historic and Forecast Sales By Regions
  • 6.6. Peritoneal Cancer Historic and Forecast Sales By Regions
  • 6.7. Fallopian Tube Cancer Historic and Forecast Sales By Regions
  • 6.8. Other Applications Historic and Forecast Sales By Regions

7. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Distribution Channel
  • 7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 7.5. Retail Pharmacies Historic and Forecast Sales By Regions
  • 7.6. Other Distribution Channels Historic and Forecast Sales By Regions

8. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE DNA REPAIR DRUGS COMPANIES

  • 9.1. DNA Repair Drugs Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF DNA REPAIR DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. AstraZeneca Plc
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Onxeo
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Johnson & Johnson
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. FoRx Therapeutics
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. AbbVie
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Artios Pharma Limited
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Pfizer Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Breakpoint Therapeutics
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Luciole Pharmaceuticals
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Merck KGaA
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. ClovisOncology Inc.
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. GlaxoSmithKline Plc
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies